Clinical Trial Update: Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating whether CYP2D6 genetic variants affect tamoxifen's effectiveness in metastatic breast cancer; the study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tamoxifen (tamoxifen)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Breast Cancer, Metastatic Disease | Phase 2 | Status: TERMINATED